Correction: Activation of IL6/IGFIR confers poor prognosis of HBV-related hepatocellular carcinoma through induction of OCT4/NANOG expression (Clinical Cancer Research (2015) 21 (201-210) DOI: 10.1158/1078-0432.CCR-13-3274);Activation of IL6/IGFIR confers poor prognosis of HBV-related hepatocellular carcinoma through induction of OCT4/NANOG expression

Clinical Cancer Research

Volumn 21, Issue 1, 2015, Pages 201-210

  Chang, Te Sheng ^a,b,c   Wu, Yu Chih ^a   Chi, Ching Chi ^b,c   Su, Wei Chi ^a   Chang, Pey Jium ^b   Lee, Kam Fai ^c   Tung, Tao Hsin ^d   Wang, Jui ^e   Liu, Jun Jen ^e   Tung, Shui Yi ^b,c   Kuo, Liang Mou ^b,c   Ho, Hong Nerng ^f,g   Ling, Thai Yen ^f   Huang, Yen Hua ^a,e,h  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^h TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; LUCIFERASE; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; SOMATOMEDIN C RECEPTOR; STAT3 PROTEIN; TRANSCRIPTION FACTOR NANOG; HOMEODOMAIN PROTEIN; NANOG PROTEIN, HUMAN; POU5F1 PROTEIN, HUMAN; SOMATOMEDIN RECEPTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; BLOOD; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HEPATITIS B VIRUS; KAPLAN MEIER METHOD; LIVER TUMOR; MOUSE; NEOPLASM RECURRENCE, LOCAL; PATHOGENICITY; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; VIROLOGY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATITIS B VIRUS; HOMEODOMAIN PROTEINS; HUMANS; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MICE; NEOPLASM RECURRENCE, LOCAL; OCTAMER TRANSCRIPTION FACTOR-3; PROGNOSIS; RECEPTORS, SOMATOMEDIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920531875     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-2538     Document Type: Erratum

References (37)

1. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, et al. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 2010;44:239-45.
2. Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 2010;59: 953-62.
3. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA. In flammation and liver cancer: new molecular links. Ann NY Acad Sci 2009;1155:206-21.
4. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998;188:341-50.
5. Hösel M, Quasdorff M, Wiegmann K, Webb D, Zedler U, Broxtermann M, et al. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 2009;50:1773-82.
6. Xiang WQ, Feng WF, Ke W, Sun Z, Chen Z, Liu W. Hepatitis B virus X protein stimulates IL-6 expression in hepatocytes via a MyD88-dependent pathway. J Hepatol 2011;54:26-33.
7. Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer 2009;124:2766-70.
8. Wang C, Yang W, Yan HX, Luo T, Zhang J, Tang L, et al. HBx induces tumorigenicity of hepatic progenitor cells in 3,5-diethoxycarbonyl-1,4- dihydrocollidine (DDC) treated HBx transgenic mice. Hepatology 2012; 55:108-20.
9. Tang Y, Kitisin K, Jogunoori W, Li C, Deng CX, Mueller SC, et al. Progenitor/ stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci U S A 2008;105:2445-50.
10. + liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 2011;9:50-63.
11. Park BC, Huh MH, Seo JH. Differential expression of transforming growth factor alpha and insulin-like growth factor II in chronic active hepatitis B, cirrhosis and hepatocellular carcinoma. J Hepatol 1995;22:286-94.
12. Iizuka N, Oka M, Yamada-Okabe H, Mori N, Tamesa T, Okada T, et al. Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res 2002;62:3939-44.
13. Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E , et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007;45:42-52.
14. Kim SO, Park JG, Lee YI. Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product. Cancer Res 1996;56:3831-6.
15. Qian J, Yao D, Dong Z, Wu W, Qiu L, Yao N, et al. Characteristics of hepatic IGF-II expression and monitored levels of circulating IGF-II mRNA in metastasis of hepatocellular carcinoma. Am J Clin Pathol 2010;134:799-806.
16. Nussbaum T, Samarin J, Ehemann V, Bissinger M, Ryschich E, Khamidjanov A, et al. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology 2008;48:146-56.
17. Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Solé M, et al. IGF activation in a molecular subclass of hepatocellular carcinoma and preclinical efficacy of IGF-IR blockage. J Hepatol 2010;52:550-9.
18. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Statistics subcommittee of the NCI-EORTC working group on cancer diagnostics. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067-72.
19. Wang XQ, Ongkeko WM, Chen L, Yang ZF, Lu P, Chen KK , et al. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4 AKT-ATP-binding cassette G2 pathway. Hepatology 2010;52:528-39.
20. Wu YC, Ling TY, Lu SH, Kuo HC, Ho HN, Yeh SD, et al. Chemotherapeutic sensitivity of testicular germ cell tumors under hypoxic conditions is negatively regulated by SENP1-controlled sumoylation of OCT4. Cancer Res 2012;72:4963-73.
21. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009;16:295-308.
22. Fransvea E, Paradiso A, Antonaci S, Giannelli G. HCC heterogeneity: molecular pathogenesis and clinical implications. Cell Oncol 2009;31: 227-33.
23. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90.
24. Arzumanyan A, Friedman T, Ng IO, Clayton MM, Lian Z, Feitelson MA. Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells? Cancer Res 2011;71:3701-8.
25. Hsia CC, Thorgeirsson SS, Tabor E. Expression of hepatitis B surface and core antigens and transforming growth factor-alpha in "oval cells" of the liver in patients with hepatocellular carcinoma. J Med Virol 1994;43: 216-21.
26. Sheen IS, Liaw YF, Chu CM, Pao CC. Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection. J Infect Dis 1992;165:831-4.
27. Rojas A, Liu G, Coleman I, Nelson PS, Zhang M, Dash R, et al. IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. Oncogene 2011;30:2345-55
28. Bendall SC, Stewart MH, Menendez P, George D, Vijayaragavan K, Werbowetski- Ogilvie T, et al. IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro. Nature 2007;448: 1015-21.
29. Wang L, Schulz TC, Sherrer ES, Dauphin DS, Shin S, Nelson AM, et al. Selfrenewal of human embryonic stem cells requires insulin-like growth factor-1 receptor and ERBB2 receptor signaling. Blood 2007;110:4111-9.
30. Huang YH, Chin CC, Ho HN, Chou CK, Shen CN, Kuo HC, et al. Pluripotency of mouse spermatogonial stem cells maintained by IGF-Idependent pathway. FASEB J 2009;23:2076-87.
31. Shan J, Shen J, Liu L, Xia F, Xu C, Duan G, et al. Nanog regulates self-renewal of cancer stem cell through IGF pathway in human hepatocellular carcinoma. Hepatology 2012;56:1004-14.
32. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012;12:159-69.
33. Allison M. Clinical setbacks reduce IGF-1 inhibitors to cocktailmixers. Nat Biotechnol 2012;30:906-7.
34. Baserga R. The decline and fall of the IGF-I receptor. J Cell Physiol 2013;228:675-9.
35. Desbois-Mouthon C, Baron A, Eggelpoël MB, Fartoux L, Venot C, Bladt F, et al. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res 2009;15:5445-56.
36. Singhal A, Jayaraman M, Dhanasekaran DN, Kohli V. Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence. Crit Rev Oncol Hemat 2012;82:116-40.
37. Kudo M. Adjuvant therapy after curative treatment for hepatocellular carcinoma. Oncology 2011;81(Suppl 1):50-5.